Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Christian Young to Cell Line, Tumor

This is a "connection" page, showing publications Christian Young has written about Cell Line, Tumor.

 
Connection Strength
 
 
 
0.743
 
  1. Nguyen KA, Keith MJ, Keysar SB, Hall SC, Bimali A, Jimeno A, Wang XJ, Young CD. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. Mol Carcinog. 2022 07; 61(7):664-676.
    View in: PubMed
    Score: 0.124
  2. Young CD, Arteaga CL, Cook RS. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Res. 2015 Dec 04; 17:148.
    View in: PubMed
    Score: 0.080
  3. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol Cell Proteomics. 2015 Jul; 14(7):1959-76.
    View in: PubMed
    Score: 0.077
  4. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, S?nchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 2013 Jul 01; 73(13):4075-85.
    View in: PubMed
    Score: 0.067
  5. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011; 6(8):e23205.
    View in: PubMed
    Score: 0.059
  6. Young CD, Anderson SM. Rah, rah, ROS: metabolic changes caused by loss of adhesion induce cell death. Breast Cancer Res. 2009; 11(6):307.
    View in: PubMed
    Score: 0.053
  7. Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 2008; 10(4):R70.
    View in: PubMed
    Score: 0.048
  8. Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Le PN, Nieto C, Chowdhury FN, Tyagi A, Lyons TR, Young CD, Zhou H, Somerset HL, Wang XJ, Jimeno A. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. Cancer Res. 2020 10 01; 80(19):4185-4198.
    View in: PubMed
    Score: 0.028
  9. Wu FL, Nolan K, Strait AA, Bian L, Nguyen KA, Wang JH, Jimeno A, Zhou HM, Young CD, Wang XJ. Macrophages Promote Growth of Squamous Cancer Independent of T cells. J Dent Res. 2019 07; 98(8):896-903.
    View in: PubMed
    Score: 0.026
  10. Luo J, Bian L, Blevins MA, Wang D, Liang C, Du D, Wu F, Holwerda B, Zhao R, Raben D, Zhou H, Young CD, Wang XJ. Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res. 2019 01 15; 25(2):808-818.
    View in: PubMed
    Score: 0.024
  11. Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther. 2018 09; 17(9):2049-2059.
    View in: PubMed
    Score: 0.024
  12. Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. J Natl Cancer Inst. 2017 11 01; 109(11).
    View in: PubMed
    Score: 0.023
  13. Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, G?mez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017 Aug 09; 9(402).
    View in: PubMed
    Score: 0.022
  14. Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6138-6150.
    View in: PubMed
    Score: 0.022
  15. Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res. 2017 Jun 30; 19(1):74.
    View in: PubMed
    Score: 0.022
  16. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, S?nchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, G?mez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb; 4(2):232-45.
    View in: PubMed
    Score: 0.017
  17. Cook RS, Garrett JT, S?nchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011 Jun 01; 71(11):3941-51.
    View in: PubMed
    Score: 0.015
  18. Lambert JR, Young CD, Persons KS, Ray R. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. Biochem Biophys Res Commun. 2007 Sep 14; 361(1):189-95.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)